Kenvue Inc. (NYSE:KVUE) Stake Increased by Nicholas Company Inc.

Nicholas Company Inc. boosted its holdings in Kenvue Inc. (NYSE:KVUE) by 7.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,623,887 shares of the company’s stock after purchasing an additional 191,103 shares during the quarter. Nicholas Company Inc. owned approximately 0.14% of Kenvue worth $56,020,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in KVUE. Grove Bank & Trust boosted its holdings in Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after purchasing an additional 947 shares during the period. Geneos Wealth Management Inc. acquired a new position in shares of Kenvue during the fourth quarter valued at $29,000. SRS Capital Advisors Inc. boosted its holdings in shares of Kenvue by 67.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after acquiring an additional 571 shares during the period. Fortitude Family Office LLC boosted its holdings in shares of Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after acquiring an additional 777 shares during the period. Finally, Versant Capital Management Inc boosted its holdings in shares of Kenvue by 300.8% during the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after acquiring an additional 1,441 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Down 1.6 %

Shares of KVUE stock opened at $22.81 on Friday. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The firm has a market cap of $43.59 billion, a PE ratio of 43.03, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. The stock has a 50 day moving average of $21.84 and a 200-day moving average of $22.38. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, equities analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were paid a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.60%. Kenvue’s payout ratio is 154.72%.

Analyst Upgrades and Downgrades

KVUE has been the subject of several analyst reports. Citigroup reduced their price target on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Wednesday, January 15th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $24.00 price objective on shares of Kenvue in a report on Monday, February 3rd. Canaccord Genuity Group upped their price objective on shares of Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. Piper Sandler upped their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a report on Monday, February 24th. Finally, Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and dropped their price target for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $23.75.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.